Some features of beckman.com will be unavailable from 8:00 p.m. PDT Saturday, December 7 until 12:00 a.m. PDT, Sunday, December 8 for planned maintenance. During this time, you will not be able to log in to use account features such as online shopping, shopping lists and order tracking.
Please ensure your orders are processed prior to this maintenance period or contact Client Services for additional assistance.
Due to the mutation-rich nature of cancer cell genomes, cancer cells often produce proteins that are incomplete or flawed. Those truncated and flawed proteins, termed neoantigens, can act as a patient-specific targets for novel immunotherapies. Since every patient’s mutation load is different – every tumor’s mutation load is different – targeting these mutant proteins can mount a focused attack on the only cells in the body where the mutant protein is expressed. By directing the immune system to attack cells that express the neoantigen, off-target effects are minimized and focused destruction of tumor cells is maximized.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.